Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2011 1
2015 1
2017 4
2018 4
2019 8
2020 6
2021 18
2022 14
2023 7
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
IgE glycosylation and impact on structure and function: A systematic review.
McCraw AJ, Palhares LCGF, Hendel JL, Gardner RA, Santaolalla A, Crescioli S, McDonnell J, Van Hemelrijck M, Chenoweth A, Spencer DIR, Wagner GK, Karagiannis SN. McCraw AJ, et al. Among authors: santaolalla a. Allergy. 2024 Oct;79(10):2625-2661. doi: 10.1111/all.16259. Epub 2024 Aug 4. Allergy. 2024. PMID: 39099223
Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial.
Zylstra J, Whyte GP, Beckmann K, Pate J, Santaolalla A, Gervais-Andre L, Russell B, Maisey N, Waters J, Tham G, Lagergren J, Green M, Kelly M, Baker C, Van Hemelrijck M, Goh V, Gossage J, Browning M, Davies A. Zylstra J, et al. Among authors: santaolalla a. Br J Sports Med. 2022 Apr;56(7):402-409. doi: 10.1136/bjsports-2021-104243. Epub 2022 Feb 1. Br J Sports Med. 2022. PMID: 35105604 Clinical Trial.
Antibodies as biomarkers for cancer risk: a systematic review.
Monroy-Iglesias MJ, Crescioli S, Beckmann K, Le N, Karagiannis SN, Van Hemelrijck M, Santaolalla A. Monroy-Iglesias MJ, et al. Among authors: santaolalla a. Clin Exp Immunol. 2022 Jul 22;209(1):46-63. doi: 10.1093/cei/uxac030. Clin Exp Immunol. 2022. PMID: 35380164 Free PMC article.
Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study.
Moore CM, Frangou E, McCartan N, Santaolalla A, Kopcke D, Brembilla G, Hadley J, Giganti F, Marsden T, Van Hemelrijck M, Gong F, Freeman A, Haider A, Tuck S, Pashayan N, Callender T, Green S, Brown LC, Punwani S, Emberton M. Moore CM, et al. Among authors: santaolalla a. BMJ Oncol. 2023 Aug 21;2(1):e000057. doi: 10.1136/bmjonc-2023-000057. eCollection 2023. BMJ Oncol. 2023. PMID: 39886504 Free PMC article.
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer.
Harris RJ, Cheung A, Ng JCF, Laddach R, Chenoweth AM, Crescioli S, Fittall M, Dominguez-Rodriguez D, Roberts J, Levi D, Liu F, Alberts E, Quist J, Santaolalla A, Pinder SE, Gillett C, Hammar N, Irshad S, Van Hemelrijck M, Dunn-Walters DK, Fraternali F, Spicer JF, Lacy KE, Tsoka S, Grigoriadis A, Tutt ANJ, Karagiannis SN. Harris RJ, et al. Among authors: santaolalla a. Cancer Res. 2021 Aug 15;81(16):4290-4304. doi: 10.1158/0008-5472.CAN-20-3773. Epub 2021 Jun 15. Cancer Res. 2021. PMID: 34224371 Free PMC article.
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver N, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Grønbæk K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Adès L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S; i4MDS consortium. Tentori CA, et al. Among authors: santaolalla a. Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. eCollection 2024 May. Hemasphere. 2024. PMID: 38756352 Free PMC article.
Risk of progression following a negative biopsy in prostate cancer active surveillance.
Beckmann K, Santaolalla A, Sugimoto M, Carroll P, Rubio J, Villers A, Bjartell A, Morgan T, Dasgupta P, Van Hemelrijck M, Elhage O; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Beckmann K, et al. Among authors: santaolalla a. Prostate Cancer Prostatic Dis. 2023 Jun;26(2):403-409. doi: 10.1038/s41391-022-00582-x. Epub 2022 Aug 25. Prostate Cancer Prostatic Dis. 2023. PMID: 36008540 Free PMC article.
Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.
Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Bruinsma SM, et al. Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Nat Rev Urol. 2017. PMID: 28290462 Free article. Review.
64 results